GlassScriptPhysician profile
Gnanaraj Joseph
NPI 1700847738
$5,286.99
in general payments reported to CMS, 2019-2025
25 companies · $28.43 in 2025
The $28.43 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,784 · 2020: $879 · 2021: $663 · 2022: $785 · 2023: $74.01 · 2024: $74.20 · 2025: $28.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $1,220.72 | 2019-2020 | |
| Olympus Corporation of The Americas | $896.40 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $740.63 | 2019-2023 | Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $415.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $288.23 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $259.31 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $180.88 | 2019-2020 | |
| Inari Medical, INC. | $146.63 | 2022 | |
| Insmed, INC. | $109.23 | 2019-2021 | |
| Genentech USA, INC. | $102.69 | 2020-2021 | |
| Pfizer INC. | $82.12 | 2019-2025 | |
| Philips North America LLC | $69.45 | 2019-2022 | |
| United Therapeutics Corporation | $64.88 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $56.01 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $55.16 | 2019 | |
| Grifols USA, LLC | $51.77 | 2020-2021 | |
| Harmony Biosciences LLC | $23.24 | 2020 | |
| Amgen INC. | $20.92 | 2021 | |
| Genzyme Corporation | $19.12 | 2022 | |
| Abbvie INC. | $15.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2020 | |
| Mylan Specialty L.P. | $12.87 | 2020 | |
| Advanced Respiratory, INC | $11.62 | 2019 | |
| Olympus America INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gnanaraj Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.